A new survey and analysis reveal that adults with tardive dyskinesia (TD) experience significantly fewer disruptions to work and school after starting treatment with INGREZZA (valbenazine). The survey found disruptions dropped from 57% before treatment to 21% after, with missed days decreasing from 5.6 to 2.0 per month. Additionally, patient-reported outcomes from the KINECT-PRO study showed meaningful improvements across physical and socio-emotional areas measured by the Tardive Dyskinesia Impact Scale (TDIS). These findings highlight INGREZZA's role in improving daily functioning and quality of life for TD patients, supporting its use as an effective treatment option.
Neurocrine Biosciences Inc (NBIX) shares are trading at USD 166.94 on Pluang as of Nov 05, 2026 20:12 WIB, showing a modest gain of 0.54% in the past day. The stock's market cap stands at $16.81 billion, reflecting its significant presence in the health sector. Investor activity on Pluang is nearly balanced with 51% buying and 49% selling, indicating steady interest in the company.
Neurocrine Biosciences reported a 41% year-over-year revenue increase to $1.123 billion in Q3 2026, fueled by strong sales of INGREZZA and rapid growth of CRENESSITY and VYKAT XR. The company is diversifying its product portfolio, reducing reliance o...
Neurocrine Biosciences is reaffirmed as a Buy with a new fair value of $195.80, representing a 19% increase from the recent price. The upgrade is driven by the company's strong Q3 results, with key drugs INGREZZA and CRENESSITY outperforming expectat...
Neurocrine Biosciences reported a 41% year-over-year revenue increase to $1.1 billion in Q3 2026, driven by strong sales of INGREZZA, CRENESSITY, and VYKAT XR. INGREZZA sales grew 17% to $801 million, prompting an upward revision of full-year 2026 gu...
